# Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform

> **NCT06344416** · NA · RECRUITING · sponsor: **Dosentrx Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Any Solid Oral Medication

## Interventions

- **DEVICE:** Use of ReX to dispense and monitor solid oral medication therapy.

## Key facts

- **NCT ID:** NCT06344416
- **Lead sponsor:** Dosentrx Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-30
- **Primary completion:** 2025-03-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06344416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06344416, "Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06344416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*